Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.

Cancer metastasis reviews - 7 Feb 2025

Ramos-Ramírez Maritza, Caballe-Pérez Enrique, Lucio-Lozada José, Romero-Nuñez Eunice, Castillo-Ruiz Cesar, Dorantes-Sánchez Lorena, Flores-Estrada Diana, Recondo Gonzalo, Barrios-Bernal Pedro, Cabrera-Miranda Luis, Bravo-Dominguez Heyman, Hernández-Pedro Norma, Arrieta Oscar

Abstract excerpt

Immune checkpoint inhibitors (ICIs) have improved clinical outcomes in patients with non-small cell lung cancer (NSCLC) lacking targetable oncogenic alterations. However, their efficacy in individuals with such genomic alterations remains heterogeneous and poorly understood. In detail, certain oncogenic alterations in TP53, EGFR (uncommon mutations), KRAS (G12C), BRAF (non-V600E), MET (amplifications), FGFR1 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to FGFR4 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunomodulation

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Tumor Microenvironment

Source

Identifiers

PMID: 39915358
DOI: 10.1007/s10555-025-10245-7

Genes

BRAF
EGFR
FGFR1
FGFR4
KRAS
MET
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy.PMID 39915358Read ↗

NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapySemantic proximity Read ↗

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions.Semantic proximity Read ↗

Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice.Semantic proximity Read ↗

Immunotherapeutic targets in non‐small cell lung cancerSemantic proximity Read ↗

Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.Semantic proximity Read ↗

Oncogene addiction and tumor mutational burden in non-small-cell lung cancer: Clinical significance and limitations.Semantic proximity Read ↗

The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.Semantic proximity Read ↗

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.Semantic proximity Read ↗

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.Semantic proximity Read ↗

Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.Semantic proximity Read ↗

The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy.Semantic proximity Read ↗

STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.